The combination of talquetamab and teclistamab induced responses in 80% of patients with the recommended phase 2 regimen. Toxic effects, including hematologic effects, cytokine release syndrome, and infection, were common.
The New England Journal of Medicine: Search Results in Hematology/Oncology
